Do you want to read an article? Please log in or register.
Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer
Lung Cancer
RECOMMENDED
Related content
COMMENTED
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Lancet Respir Med.
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M
doi: 10.1016/S2213-
RECOMMENDED
Lung Cancer
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M, CRISP Registry Group.
doi: 10.1016/j.lungcan.2020.10.012
Lung Cancer
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Lancet Respir Med.
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC
RECOMMENDED
Lung Cancer
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P
doi: 10.1016/j.cllc.2021.03.006
RECOMMENDED
Lung Cancer
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for RET Fusions
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Med (Lausanne)
Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI
doi: 10.3389/fmed.2020.562480
RECOMMENDED
Lung Cancer
Definitive treatment patterns and survival in stage II non-small cell lung cancer
doi: 10.1016/j.lungcan.
Lung Cancer
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States
Clin Lung Cancer.
Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, Sedrak M, Massarelli E, Welsh JW, Amini A
doi: 10.1016/j.cllc.2020.09.004.
RECOMMENDED
Lung CancerPleural DiseasesFurther Publications
Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
Chest.
Suresh K, Naidoo J, Lin CT, Danoff S
doi: 10.1016/
RECOMMENDED
Lung Cancer
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug
Lung Cancer.
Stahel RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, Sandner U, Opitz I, Andratschke N, Franzen D, Dimopoulou G, Matthes KL, Kohler M, Guckenberger M, Weder W
doi: 10.1016/j.lungcan.2020.05.037.